IBD Prognosis via Multi-Marker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and prognosing inflammatory bowel disease (IBD) are inadequate, particularly in differentiating it from irritable bowel syndrome and predicting disease progression and response to therapy, leading to delayed and ineffective treatment.
Innovation Solution
A method involving the analysis of serological, protein, and genetic markers to create a marker profile, which is then analyzed statistically to provide a prognostic or therapeutic profile for predicting disease progression, response to therapy, and selecting appropriate treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for IBD, then basic diagnosis can be made, but the accuracy of differentiating IBD from IBS and predicting disease progression is insufficient
Solution Approach 1:
The diagnostic approach is segmented into multiple independent marker analyses (serological markers like ASCA, pANCA, anti-OmpC; genetic markers like NOD2; protein markers like CRP, SAA). Each marker provides independent diagnostic information that can be combined to achieve superior accuracy in differentiating IBD from IBS and predicting disease progression, resolving the contradiction between basic diagnostic capability and comprehensive prognostic information.
Solution Approach 2:
The invention creates a composite diagnostic profile by combining multiple types of markers (serological, genetic, protein) into a unified assessment system. This composite approach leverages the strengths of each marker type while compensating for their individual limitations, achieving both accurate differentiation of IBD from IBS and reliable prediction of disease progression that neither marker type could achieve alone.
2Reliability
If multiple markers are analyzed to improve prognosis accuracy, then predictive capability improves, but the complexity of the diagnostic system increases
Solution Approach 1:
The complex prognostic assessment is segmented into separate, manageable marker categories (serological, genetic, protein markers), each evaluated independently through standardized tests. This segmentation allows the system to handle complexity systematically, with each component contributing specific prognostic information while maintaining clear analytical boundaries that simplify the overall process.
Solution Approach 2:
The multi-marker system serves multiple functions simultaneously: it differentiates IBD from IBS, predicts disease progression, identifies patients at risk for complications, and guides treatment decisions. By making the diagnostic system multi-functional, the invention justifies the increased complexity through the gain in reliability and the ability to address multiple clinical questions with a single comprehensive assessment.
3Loss of time
If rapid and sensitive testing methods are implemented, then early detection improves, but the cost of testing increases
Solution Approach 1:
The testing protocol is segmented into priority-based marker assessments, allowing rapid detection of high-yield markers (such as ASCA, pANCA, anti-OmpC) that provide immediate diagnostic value, while less critical markers can be evaluated subsequently. This segmented approach enables early detection of IBD with high sensitivity while managing testing resources efficiently by focusing initial efforts on the most informative markers.
Solution Approach 2:
The system applies partial action by selecting and analyzing only the most clinically relevant markers from the full spectrum of available options, rather than universally testing all possible markers. This partial approach to multi-marker analysis achieves rapid and sensitive detection for the primary diagnostic questions while reducing the quantity of testing resources required compared to comprehensive testing of all markers.
Data Source
AI summary
The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery.